Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer.

Sami Alexander SafiLena HaeberleAlexander RehdersStephen FungSascha VaghiriChristoph RoderburgTom LueddeFarid Ziayee Irene Esposito Georg FluegenWolfram Trudo Knoefel

Published in: Cancers (2021)

MPE remains warranted after neoadjuvant therapy. Mesopancreatic fat invasion was still evident in the majority of our patients following neoadjuvant treatment. MDCT-predicted tumor response did not exclude mesopancreatic fat infiltration.

Keyphrases

rectal cancer
adipose tissue
lymph node
locally advanced
end stage renal disease
chronic kidney disease
newly diagnosed
stem cells
prognostic factors
peritoneal dialysis
combination therapy